Seven Fleet Capital Management LP bought a new stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report) in the fourth quarter, HoldingsChannel.com reports. The firm bought 4,000 shares of the company’s stock, valued at approximately $986,000. Krystal Biotech makes up about 0.7% of Seven Fleet Capital Management LP’s holdings, making the stock its 24th biggest holding.
Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Soleus Capital Management L.P. grew its holdings in shares of Krystal Biotech by 108.9% in the second quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company’s stock worth $126,870,000 after acquiring an additional 481,200 shares during the period. Norges Bank purchased a new position in Krystal Biotech in the fourth quarter worth about $70,159,000. William Blair Investment Management LLC boosted its position in Krystal Biotech by 152.1% in the fourth quarter. William Blair Investment Management LLC now owns 376,340 shares of the company’s stock worth $92,783,000 after purchasing an additional 227,038 shares during the last quarter. Janus Henderson Group PLC grew its stake in shares of Krystal Biotech by 2,078.9% during the 4th quarter. Janus Henderson Group PLC now owns 219,440 shares of the company’s stock valued at $54,147,000 after purchasing an additional 209,369 shares during the period. Finally, UBS Group AG grew its stake in shares of Krystal Biotech by 970.8% during the 4th quarter. UBS Group AG now owns 159,595 shares of the company’s stock valued at $39,347,000 after purchasing an additional 177,922 shares during the period. 86.29% of the stock is owned by institutional investors.
Krystal Biotech Stock Up 1.9%
Shares of KRYS opened at $348.06 on Friday. The business has a 50-day simple moving average of $294.24 and a two-hundred day simple moving average of $271.55. Krystal Biotech, Inc. has a 52 week low of $130.17 and a 52 week high of $356.50. The stock has a market cap of $10.26 billion, a price-to-earnings ratio of 46.53 and a beta of 0.53.
Insider Buying and Selling
In other Krystal Biotech news, EVP John Charles Thomas sold 642 shares of the company’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $302.03, for a total value of $193,903.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $308.11, for a total transaction of $7,702,750.00. Following the completion of the transaction, the insider owned 1,378,155 shares of the company’s stock, valued at approximately $424,623,337.05. The trade was a 1.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.10% of the stock is currently owned by company insiders.
Analyst Upgrades and Downgrades
Several research firms have recently commented on KRYS. HC Wainwright upped their price target on shares of Krystal Biotech from $310.00 to $361.00 and gave the company a “buy” rating in a research report on Tuesday. Wolfe Research initiated coverage on shares of Krystal Biotech in a research report on Friday, March 27th. They set a “peer perform” rating for the company. Weiss Ratings raised shares of Krystal Biotech from a “buy (b-)” rating to a “buy (b)” rating in a report on Tuesday. Citigroup upped their target price on shares of Krystal Biotech from $371.00 to $378.00 and gave the company a “buy” rating in a report on Tuesday, May 5th. Finally, Guggenheim increased their price target on shares of Krystal Biotech from $224.00 to $284.00 and gave the stock a “buy” rating in a research report on Wednesday, February 25th. Ten analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $340.56.
Read Our Latest Research Report on Krystal Biotech
Krystal Biotech Profile
Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.
The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.
Featured Stories
- Five stocks we like better than Krystal Biotech
- Credo Technologies Accelerates AI—Its Stock Price Will Follow
- Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA
- Jabil Just Gave Investors a Stronger Reason to Buy the Dip
- CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge
Want to see what other hedge funds are holding KRYS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report).
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
